Sarepta Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.2 | $1.9 | $1.2 | $0.9 | $0.7 |
| Operating income | -$0.7 | $0.2 | -$0.3 | -$0.5 | -$0.5 |
| Net income | -$0.7 | $0.2 | -$0.5 | -$0.7 | -$0.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$0.3 | -$0.3 | -$0.6 | -$0.4 | -$0.5 |
| Share repurchases | $<0.1 | $0.0 | $0.0 | — | — |
Shares outstanding 105.6M · Free float 79.7%
Annual filing data through FY ended December 31, 2025; float as of October 8, 2026.